Shares of Ipca Laboratories declined 2.12% to Rs 1,370.20 in Tuesday's session. The stock is part of the Nifty Midcap 150 index.
Quarterly Financials:
The consolidated quarterly revenue and net profit are detailed below:
| Heading | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 2,092.63 Crore | Rs 2,354.90 Crore | Rs 2,245.37 Crore | Rs 2,246.69 Crore | Rs 2,308.85 Crore |
| Net Profit | Rs 198.98 Crore | Rs 245.44 Crore | Rs 277.33 Crore | Rs 65.78 Crore | Rs 234.42 Crore |
| EPS | 7.58 | 9.05 | 9.78 | 2.67 | 9.19 |
The revenue for the quarter ending June 2025 was Rs 2,308.85 Crore, an increase compared to Rs 2,246.69 Crore in March 2025. The net profit for the quarter ending June 2025 was Rs 234.42 Crore, compared to Rs 65.78 Crore in March 2025.
Annual Financials:
The consolidated annual revenue, net profit, and other key financial indicators are as follows:
| Heading | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 5,419.99 Crore | Rs 5,829.79 Crore | Rs 6,244.32 Crore | Rs 7,705.04 Crore | Rs 8,939.59 Crore |
| Net Profit | Rs 1,148.84 Crore | Rs 910.95 Crore | Rs 491.93 Crore | Rs 529.21 Crore | Rs 787.53 Crore |
| EPS | 45.01 | 34.85 | 18.58 | 25.82 | 35.14 |
| BVPS | 371.79 | 219.51 | 233.16 | 304.57 | 273.88 |
| ROE | 24.24 | 16.09 | 8.06 | 8.64 | 10.61 |
| Debt to Equity | 0.05 | 0.14 | 0.25 | 0.22 | 0.19 |
The revenue for the year ending March 2025 was Rs 8,939.59 Crore, an increase compared to Rs 7,705.04 Crore in March 2024. The net profit for the year ending March 2025 was Rs 787.53 Crore, compared to Rs 529.21 Crore in March 2024. The debt-to-equity ratio as of March 2025 stood at 0.19.
Annual Income Statement:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Sales | Rs 8,939 Crore | Rs 7,705 Crore | Rs 6,244 Crore | Rs 5,829 Crore | Rs 5,419 Crore |
| Other Income | Rs 92 Crore | Rs 124 Crore | Rs 125 Crore | Rs 66 Crore | Rs 62 Crore |
| Total Income | Rs 9,032 Crore | Rs 7,829 Crore | Rs 6,369 Crore | Rs 5,896 Crore | Rs 5,482 Crore |
| Total Expenditure | Rs 7,816 Crore | Rs 6,848 Crore | Rs 5,579 Crore | Rs 4,752 Crore | Rs 4,084 Crore |
| EBIT | Rs 1,216 Crore | Rs 980 Crore | Rs 790 Crore | Rs 1,143 Crore | Rs 1,398 Crore |
| Interest | Rs 84 Crore | Rs 138 Crore | Rs 45 Crore | Rs 7 Crore | Rs 9 Crore |
| Tax | Rs 343 Crore | Rs 313 Crore | Rs 253 Crore | Rs 224 Crore | Rs 240 Crore |
| Net Profit | Rs 787 Crore | Rs 529 Crore | Rs 491 Crore | Rs 910 Crore | Rs 1,148 Crore |
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | |
|---|---|---|---|---|---|
| Sales | Rs 2,308 Crore | Rs 2,246 Crore | Rs 2,245 Crore | Rs 2,354 Crore | Rs 2,092 Crore |
| Other Income | Rs 32 Crore | Rs 25 Crore | Rs 20 Crore | Rs 26 Crore | Rs 20 Crore |
| Total Income | Rs 2,341 Crore | Rs 2,272 Crore | Rs 2,265 Crore | Rs 2,381 Crore | Rs 2,113 Crore |
| Total Expenditure | Rs 1,992 Crore | Rs 2,123 Crore | Rs 1,880 Crore | Rs 2,013 Crore | Rs 1,798 Crore |
| EBIT | Rs 349 Crore | Rs 149 Crore | Rs 384 Crore | Rs 367 Crore | Rs 314 Crore |
| Interest | Rs 18 Crore | Rs 21 Crore | Rs 16 Crore | Rs 22 Crore | Rs 24 Crore |
| Tax | Rs 96 Crore | Rs 62 Crore | Rs 90 Crore | Rs 99 Crore | Rs 91 Crore |
| Net Profit | Rs 234 Crore | Rs 65 Crore | Rs 277 Crore | Rs 245 Crore | Rs 198 Crore |
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Operating Activities | Rs 1,321 Crore | Rs 944 Crore | Rs 805 Crore | Rs 856 Crore | Rs 1,090 Crore |
| Investing Activities | Rs -869 Crore | Rs -1,291 Crore | Rs -725 Crore | Rs -855 Crore | Rs -520 Crore |
| Financing Activities | Rs -282 Crore | Rs -552 Crore | Rs 507 Crore | Rs 426 Crore | Rs -305 Crore |
| Others | Rs 0 Crore | Rs 76 Crore | Rs 0 Crore | Rs 4 Crore | Rs 0 Crore |
| Net Cash Flow | Rs 168 Crore | Rs -823 Crore | Rs 588 Crore | Rs 431 Crore | Rs 263 Crore |
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Share Capital | Rs 25 Crore | Rs 25 Crore | Rs 25 Crore | Rs 25 Crore | Rs 25 Crore |
| Reserves & Surplus | Rs 6,923 Crore | Rs 6,306 Crore | Rs 5,816 Crore | Rs 5,466 Crore | Rs 4,676 Crore |
| Current Liabilities | Rs 2,386 Crore | Rs 2,355 Crore | Rs 1,805 Crore | Rs 1,465 Crore | Rs 1,160 Crore |
| Other Liabilities | Rs 2,425 Crore | Rs 2,413 Crore | Rs 978 Crore | Rs 681 Crore | Rs 206 Crore |
| Total Liabilities | Rs 11,760 Crore | Rs 11,101 Crore | Rs 8,626 Crore | Rs 7,638 Crore | Rs 6,068 Crore |
| Fixed Assets | Rs 4,798 Crore | Rs 4,805 Crore | Rs 2,853 Crore | Rs 2,669 Crore | Rs 2,260 Crore |
| Current Assets | Rs 6,268 Crore | Rs 5,538 Crore | Rs 5,189 Crore | Rs 4,457 Crore | Rs 3,436 Crore |
| Other Assets | Rs 694 Crore | Rs 756 Crore | Rs 583 Crore | Rs 511 Crore | Rs 370 Crore |
| Total Assets | Rs 11,760 Crore | Rs 11,101 Crore | Rs 8,626 Crore | Rs 7,638 Crore | Rs 6,068 Crore |
| Contingent Liabilities | Rs 613 Crore | Rs 303 Crore | Rs 2,125 Crore | Rs 274 Crore | Rs 369 Crore |
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Basic EPS (Rs.) | 35.14 | 25.82 | 18.58 | 34.85 | 45.01 |
| Diluted Eps (Rs.) | 29.08 | 21.57 | 18.58 | 34.85 | 45.01 |
| Book Value [Excl. Reval Reserve]/Share (Rs.) | 273.88 | 304.57 | 233.16 | 219.51 | 371.79 |
| Dividend/Share (Rs.) | 4.00 | 4.00 | 4.00 | 4.00 | 8.00 |
| Face Value | 1 | 1 | 1 | 1 | 2 |
| Gross Profit Margin (%) | 20.34 | 18.76 | 16.85 | 23.59 | 29.65 |
| Operating Margin (%) | 15.89 | 14.12 | 12.66 | 19.61 | 25.79 |
| Net Profit Margin (%) | 8.80 | 6.86 | 7.87 | 15.62 | 21.19 |
| Return on Networth / Equity (%) | 10.61 | 8.64 | 8.06 | 16.09 | 24.24 |
| ROCE (%) | 15.15 | 12.44 | 11.59 | 18.52 | 28.48 |
| Return On Assets (%) | 6.27 | 4.93 | 5.46 | 11.57 | 18.78 |
| Current Ratio (X) | 2.63 | 2.35 | 2.87 | 3.04 | 2.96 |
| Quick Ratio (X) | 1.55 | 1.30 | 1.91 | 1.77 | 1.59 |
| Debt to Equity (x) | 0.19 | 0.22 | 0.25 | 0.14 | 0.05 |
| Interest Coverage Ratios (X) | 21.42 | 10.46 | 23.11 | 178.91 | 177.79 |
| Asset Turnover Ratio (%) | 0.78 | 0.78 | 0.77 | 0.80 | 0.91 |
| Inventory Turnover Ratio (X) | 3.55 | 1.05 | 0.95 | 0.96 | 1.10 |
| 3 Yr CAGR Sales (%) | 23.83 | 19.23 | 15.90 | 24.30 | 28.99 |
| 3 Yr CAGR Net Profit (%) | -7.02 | -32.13 | -10.30 | 43.23 | 117.14 |
| P/E (x) | 42.74 | 47.92 | 43.61 | 30.58 | 21.15 |
| P/B (x) | 5.48 | 4.96 | 3.52 | 4.90 | 5.13 |
| EV/EBITDA (x) | 22.26 | 23.45 | 19.23 | 19.73 | 14.96 |
| P/S (x) | 4.26 | 4.08 | 3.29 | 4.62 | 4.45 |
Ipca Laboratories announced a final dividend of Rs 2.00 per share (200%) with an effective date of August 5, 2025. Earlier dividends include an interim dividend of Rs 2.00 per share (200%) on November 25, 2024, and a final dividend of Rs 2.00 per share (200%) on August 6, 2024.
The company had a stock split on January 10, 2022, where the face value changed from Rs 2 to Rs 1. A prior stock split occurred on March 22, 2010, changing the face value from Rs 10 to Rs 2.
A bonus issue was announced on October 27, 2004, with a bonus ratio of 1:1 and an ex-bonus date of January 28, 2005.
The company has been the subject of several corporate announcements, including disclosures under Regulation 29(2) of SEBI (SAST) Regulations, 2011, and outcomes from analyst/investor meetings.
Moneycontrol analysis, as of August 22, 2025, indicates a neutral sentiment on the stock.
Ipca Laboratories shares fell 2.12% in Tuesday's trading session.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
